Thermosome Closes Exclusive Global Licensing Agreement with Avenor Therapeutics

— Agreement covers Thermosome’s proprietary thermosensitive liposome (TSL) platform and Phase II-ready lead candidate THE001
— Deal builds on encouraging Phase I clinical data and FDA and EMA Orphan Drug Designation for THE001
— TSL platform to be combined with CE-marked radiative precision hyperthermia system, suitable for combination with both radio- and chemotherapy, forming a best-in-class drug-device combination
Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced an exclusive global licensing deal with Avenor Therapeutics, Cambridge, MA, USA. Under the agreement, Avenor has secured an exclusive worldwide license for Thermosome’s thermosensitive liposome (TSL) technology and platform portfolio, including seven patent families, and the Phase II-ready lead candidate THE001, which has received FDA and EMA Orphan Drug Designation for soft tissue sarcomas. Financial details of the agreement were not disclosed.
EktaH Advances First-in-Class Obesity Treatment NKS-3 into Phase II Clinical Development

— First patient recruited for Phase IIa clinical trial
— EUR 2.4 million in non-dilutive funding secured from Bpifrance
— Final results of Phase I study expected in Q1 2027
EktaH, a clinical-stage biotechnology company developing first-in-class oral therapies for obesity and metabolic diseases, today announced that it has advanced its lead compound NKS-3 into Phase II clinical development for the treatment of obesity. The first patient has been recruited for the exploratory Phase IIa SERENITY-1 study (NCT07882654) in Tunisia.
In parallel, EktaH has secured EUR 2.4 million in non-dilutive funding from Bpifrance to support further clinical development, including a larger Phase II study planned in France. Read more…
New Kidney International Study Provides Preclinical Proof-of-Concept for TolerogenixX’s MIC Platform in Lupus Nephritis
![]()
- Extends proprietary immunoregulatory MIC platform into autoimmune disease
- Tolerance-inducing approach designed to correct dysregulated immune responses rather than only suppress inflammation
- Potential to reduce the long-term treatment burden associated with multi-drug immunosuppression
TolerogenixX, a clinical-stage biopharmaceutical company developing personalized cell therapies to induce antigen-specific immune tolerance, today announced that a new study in Kidney International provides preclinical proof-of-concept for its Modified Immune Cells (MIC) platform in lupus nephritis, a severe manifestation of systemic lupus erythematosus (SLE).





